As an acquired thrombophilia, cancer inflammation in the microenvironment induces a pro-inflammatory response including the release of Tumor Necrosis Factor Alpha (TNF-alpha) and cytokines including interleukins 1a, 6, 17, and 18 (Setiawan et al., 2022). This evidence concerns the gene TNF and Rare hereditary thrombophilia.